Skip to main content
. 2011 Oct 22;80(1):89–100. doi: 10.3797/scipharm.1109-03

Tab. 3.

Data of linearity studies for ANT, CBZ, FSD, and PHTN

Conc. (μM) Mean Peak Area ± S.D., R.S.D. (%)

ANT CBZ FSD PHTN
5 33934.5 ± 130.8; 0.38 73873.3 ± 666.3; 0.91 106796.3 ± 1187.9; 1.11 61020.0 ± 400.2; 0.65
10 74048.5 ± 1948.1; 2.63 159297.5 ± 4349.4; 2.73 220881.0 ± 5107.4; 2.31 132452.5 ± 1699.2; 1.28
20 147243.0 ± 861.25; 0.58 314557.3 ± 1862.6; 0.59 443556.3 ± 1103.3; 0.25 264798.0 ± 625.1; 0.24
30 225102.5 ± 1723.2; 0.76 483318.7 ± 2727.5; 0.56 677090.7 ± 1529.9; 0.22 407881.0 ± 1223.3; 0.29
40 297507.0 ± 381.8; 0.13 644809.0 ± 1289.9; 0.20 900838.7 ± 2264.2; 0.25 544944.5 ± 1320.2; 0.24
60 459703.0 ± 445.9; 0.09 966179.0 ± 5876.6; 0.61 1341402.0 ± 1512.6; 0.11 814444.0 ± 1694.2; 0.21
80 614150.3 ± 1137.8; 0.18 1274946.0 ± 3176.9; 0.25 1773965.0 ± 2945.5; 0.17 1076016.0 ± 2026.6; 0.19
100 776083.0 ± 76.4; 0.01 1612014.0 ± 6691.5; 0.41 2223262.0 ± 4658.7; 0.21 1358006.0 ± 653.4; 0.05
Equ. y = 7765.3x − 5694 y = 16113x − 3773 y = 22256x + 1535.3 y = 13596x − 3881
(r2) 0.999 1.000 0.999 1.000